On April 26, BJUT signed a contract with Hainan Poly Pharm Co., Ltd. to promote the transformation of the achievements of the “COVID-19 Medicine” project led by the Professor Gao Xueyun from the Faculty of Environment and Life.

The “COVID-19 Medicine” represents a breakthrough achieved by the Professor Gao Xueyun’s team after more than 10 years’ research. The innovative drug, which targets conservative main proteases of coronavirus, is expected to overcome the inefficiency of common vaccines and antibody drugs in response to mutant strains. The preliminary animal test evaluation from Chinese Center for Disease Control and Prevention showed that the drug had a huge potential of being superior to Remdesivir and IFN. These achievements have been submitted for China, USA and international patent applications under the PCT, and the drug will enter major countries worldwide through PCT.

The mechanism of the product is expected to achieve another breakthrough in COVID-19 treatment, and will become an important milestone for Chinese drug companies to gain worldwide recognition.